How We Partner

Late-Stage Clinical Supply

Kevin Ingham

"The combination of the J.POD® facility design and our standardized platform are enabling us to seamlessly transfer work around the globe as needed by our customers. For example, we can be manufacturing late-phase clinical material at our J.POD in the US, and we can then quickly transfer that process for commercialization to the J.POD facility in France.

Our unique continuous manufacturing platform technology can also de-risk supply by producing huge quantities of antibody mass in fewer batches and at smaller scale than traditional batch manufacturing. This allows our partners to save time, energy, and resources all along the path to commercialization, rather than being forced to increase bioreactor size (scale-up) or bioreactor quantity (scale-out) as their CMC progresses.”

Kevin Ingham, Manufacturing Operations and Site Head, Redmond, US

Late-Stage Clinical & Ph III Supply

We possess the capability to provide support for late-stage clinical programs, regardless of whether an intensified process has been developed beforehand. By leveraging existing cell lines and transitioning from fed-batch to perfusion and fully continuous modes, we mitigate the scaling-up risks while reaping the benefits of lower commercial COGS and a more adaptable supply chain.

  • Fed-batch process assessment and conversion to continuous mode
  • Process characterization, validation & PPQ campaigns
  • Ph III DS manufacturing
    • 500/1000L scale enabling up to 50 kg batch
    • One J.POD facility offers a mass output of up to 2,000 kg/year
  • Stability studies
  • Regulatory support/ Market launch assistance

Continuous manufacturing emerges as the ideal solution for molecules, especially those with uncertain future indications or potentially facing increasing mass demand over time, offering unparalleled flexibility to meet evolving needs.

No Scale-up From Late-State Clinical to Commercial Supply

Our continuous bioprocessing platform inherently avoids the typical challenges encountered with traditional process scale-up strategies. This encompasses the scale-up of bioreactors and potential technology transfer to larger-scale manufacturing facilities.

1 1 1 3 2 F JEB focus areaa

Flexible Ph III Supply Chain

We can adapt the duration of our manufacturing process to match supply demand and meet from low needs (ADCs, orphan indications) to high mass outputs (>>500kg) in our own J.POD network.

1 1 1 3 2 Q JEB focus area

Additional trains can be added into an existing facility

  • Maximum flexibility for build out of facilities
  • Limited CAPEX at the beginning
  • Fully adjustable to clinical and market needs

Contact Our Experts

Philip Boehme

Philip Boehme

EVP Partnering & Transformation

Logo Just white
Just – Evotec Biologics is a mission-driven Business Unit of Evotec with the aim of radically improving access to biologics through a de-risked, agile approach, coupled with significantly lower manufacturing cost. Over the years we have advanced an industry-transforming bioprocessing platform, which we leverage with our partners to drive what we call the paradigm shift in biologics.